A Novel Treatment for Symptomatic Heart Failure

The only direct treatment for high left atrial pressures (LAP)

The Corvia Atrial Shunt is about the size of a euro.

The Corvia Atrial Shunt is a novel, minimally invasive cardiac implant for patients suffering from Heart Failure with Preserved Ejection Fraction (HFpEF) or Mildy Reduced Ejection Fraction (HFmrEF). Designed to reduce elevated LAP, the primary contributor to HF symptoms, the Corvia Atrial Shunt offers the most advanced therapeutic option for HF patients with an EF≥40%.

The Corvia Atrial Shunt is the most widely studied interatrial shunt for heart failure. It has been implanted in over 550 patients worldwide, and more than 50 patients have had the shunt for over 5 years.1

Dynamic Decompression

Atrial shunting safely relieves the high pressures that cause HF symptoms by connecting the two upper chambers of the heart. This connection allows the heart to dynamically decompress by directing blood from the left to right atrium on demand, thereby reducing HF symptoms.


The Corvia Atrial Shunt is placed by an interventional
cardiologist or electrophysiologist during a one-time
procedure. A catheter is used to place a Corvia Atrial Shunt
as a passage between the left and right atria. This passage
allows blood to flow from the high pressure left atrium to the
lower pressure right atrium, thereby reducing pressure in the
lungs and left side of the heart.


By facilitating continuous and dynamic decompression of the left atrium, the Corvia Atrial Shunt has been shown to reduce heart failure hospitalizations and improve heart failure symptoms and quality of life.2,3


After 1 year, 71% of patients had fewer HF symptoms3


After 3 years, 75% of patients reported an improved quality of life4


After 3 years, 69%
of patients had no hospitalizations for heart failure4

  1. Unpublished data on file at Corvia Medical. Data as of August 1, 2022.
  2. Feldman T, Mauri L, Kahwash, et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I): A Phase 2, Randomized, Sham-Controlled Trial. Circ. 2018;137(4):364-375.
  3. Kaye D, Hasenfuß G, Neuzil P, et al. One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2016;9(12):e003662.
  4. Unpublished data from REDUCE LAP-HF (n=64). Data on file at Corvia Medical.